The NSCLC tumors have high molecular heterogeneity, exhibiting gene mutations in B-Raf proto-oncogene, serine/threonine kinase (BRAF), KRAS proto-oncogene, and activating mutations of epidermal growth factor receptor (EGFR) [12]. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.